European Bank of Induced Pluripotent Stem Cells (EBiSC)

EBiSC - European Bank for induced pluripotent Stem Cells

The European Bank for induced pluripotent Stem Cells (EBiSC) is a large European public-private partnership project supported jointly by the Innovative Medicines Initiative (IMI) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), which aims at establishing the first European Bank for induced pluripotent Stem Cells (iPSC).

About EBiSC

Sanger Institute, Genome Research Limited
The Cellular Generation and Phenotyping (CGaP) facility at the Sanger Institute is a major contributor of iPSC lines to the EBiSC bank, providing high-quality control iPSC lines derived in the HipSci project, which are further expanded and banked for the EBiSC collection. We have internal Quality Control measures that enable us to ensure a consistent quality cell lines are provided to the project.

The European Bank for induced pluripotent Stem Cells (EBiSC) aims to:

  • Provide quality-controlled, disease-relevant research-grade iPSC lines, data and cell services
  • Create and run a worldwide iPSC lines banking and distribution service to internationally accepted quality criteria.
  • Establish in Europe a centralised, not-for-profit iPSC lines bank for academia and industry to provide consistent, high-quality tools for new medicines development.

EBiSC’s capacity will be 10,000 cell lines; it will eventually process over 1,000 lines per year.

Sanger Institute, Genome Research Limited
The EBiSC Consortium includes stakeholders at all levels of iPSC line generation and use (from tissue donors to clinical and academic iPSC researchers and industrial users), ensuring that it has the scientific expertise, facilities, networks and experience necessary to achieve its goals. Led by Pfizer Ltd and managed by Roslin Cells, the Consortium comprises eight active participant iPSC Centres with clinical and patient networks, a global leader in industrial iPSC supply, international experts in iPSC science, biobanking, bioengineering and regenerative medicine, and scholars in law and ethics.

The main facility will be at the Babraham Research Campus (Cambridge, UK) and will undertake cell expansion, Quality Control and characterisation. The European Cell Culture Collection (ECACC) of Public Health England (Department of Health, UK) will coordinate cell line distribution. The Fraunhofer IBMT (Saarbrücken, Germany) will provide comprehensive operational back up.

Contact

If you need help or have any queries, please contact us using the details below.

Sanger people

Photo of Professor Ludovic Vallier, FMedSci

Professor Ludovic Vallier, FMedSci

Honorary Faculty (formerly Senior Group Leader at the Sanger Institute)

External partners and funders

External

Vallier, Ludovic

Ludovic Vallier was jointly based at the Cambridge Stem Cell Institute and the Wellcome Sanger Institute. His laboratory studies the basic mechanisms controlling differentiation of human pluripotent cells into pancreas, lung, gut and liver cells. His overall objective is not only to investigate molecular mechanisms of differentiation but also to generate cell types for clinical studies and for cell based therapy.

External

Pfizer Ltd

United Kingdom

External

Novo Nordisk A/S

Denmark

External

AstraZeneca AB

Sweden

External

H. Lundbeck A/S

Denmark

External

UCB Biopharma SPRL

Belgium

External

Bayer Pharma AG

Germany

External

Eli Lilly & Co.

United Kingdom

External

Roslin Cell Sciences

United Kingdom

External

ARTTIC

France

External

DefiniGEN Ltd

United Kingdom

External

Bioneer A/S

Denmark

External

University of Edinburgh

United Kingdom

External

University of Newcastle Upon Tyne

United Kingdom

External

University College London

United Kingdom

External

Inbiomed

Spain